It’s time to take a short break from the immunometabolism mini-series and turn our attention to aggressive lymphomas such as diffuse large B cell lymphomas (DLBCL).
This week heralded the latest AACR virtual meeting on Advances in Lymphoma in conjunction with iCML. There were plenty of science focused talks to listen to and learn from, including new developments in oncogenic targeting.
What if we can learn from what the patients underlying biology can teach us in terms of more rationally designed clinical trials?
We know these are diverse and heterogeneous tumours, but this doesn’t mean we can’t take a more precision medicine approach to treating patients. What can we learn from early trial readouts and genetic analyses?
It turns out, the answer is quite a bit and more information might be available at the forthcoming ASH meeting, so let’s look at what we can piece together from the available data now…